AbbVie Broadcasts European Fee Approval of SKYRIZI ® (risankizumab) for the Remedy of Adults with Reasonably to Severely Energetic Ulcerative Colitis
The advertising authorization for SKYRIZI ® (risankizumab) marks its fourth accredited indication within the European UnionThe approval is supported by ...
